Knott David M Jr Increases Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Knott David M Jr boosted its position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 4.8% in the 4th quarter, Holdings Channel reports. The firm owned 128,000 shares of the company’s stock after buying an additional 5,856 shares during the quarter. Syndax Pharmaceuticals accounts for approximately 0.6% of Knott David M Jr’s portfolio, making the stock its 23rd biggest position. Knott David M Jr’s holdings in Syndax Pharmaceuticals were worth $1,692,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the company. R Squared Ltd purchased a new stake in Syndax Pharmaceuticals in the fourth quarter worth $26,000. Quantbot Technologies LP bought a new position in shares of Syndax Pharmaceuticals in the third quarter worth about $49,000. Cape Investment Advisory Inc. increased its stake in Syndax Pharmaceuticals by 157.1% in the 4th quarter. Cape Investment Advisory Inc. now owns 6,427 shares of the company’s stock worth $85,000 after buying an additional 3,927 shares during the period. KBC Group NV grew its stake in Syndax Pharmaceuticals by 104.8% in the 4th quarter. KBC Group NV now owns 6,954 shares of the company’s stock worth $92,000 after acquiring an additional 3,559 shares in the last quarter. Finally, E Fund Management Co. Ltd. increased its position in shares of Syndax Pharmaceuticals by 14.4% during the fourth quarter. E Fund Management Co. Ltd. now owns 12,603 shares of the company’s stock worth $167,000 after acquiring an additional 1,583 shares during the period.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Scotiabank lowered their price target on Syndax Pharmaceuticals from $18.00 to $16.00 and set a “sector perform” rating for the company in a report on Wednesday, January 8th. JPMorgan Chase & Co. upped their target price on Syndax Pharmaceuticals from $39.00 to $41.00 and gave the stock an “overweight” rating in a report on Thursday, March 20th. HC Wainwright restated a “buy” rating and set a $51.00 price target on shares of Syndax Pharmaceuticals in a research note on Tuesday, March 4th. Finally, Citigroup lowered their price objective on shares of Syndax Pharmaceuticals from $45.00 to $42.00 and set a “buy” rating for the company in a research note on Tuesday, March 4th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $36.20.

Insider Buying and Selling

In related news, CFO Keith A. Goldan sold 3,777 shares of Syndax Pharmaceuticals stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $15.50, for a total value of $58,543.50. Following the completion of the sale, the chief financial officer now directly owns 90,746 shares in the company, valued at $1,406,563. This trade represents a 4.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Michael A. Metzger sold 13,288 shares of the company’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $15.50, for a total transaction of $205,964.00. Following the transaction, the chief executive officer now owns 300,121 shares in the company, valued at $4,651,875.50. The trade was a 4.24 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 21,683 shares of company stock worth $336,087 in the last ninety days. 4.10% of the stock is owned by insiders.

Syndax Pharmaceuticals Stock Performance

SNDX stock opened at $12.28 on Tuesday. Syndax Pharmaceuticals, Inc. has a one year low of $12.06 and a one year high of $25.07. The firm has a market cap of $1.06 billion, a price-to-earnings ratio of -3.38 and a beta of 0.92. The firm has a 50-day simple moving average of $14.28 and a two-hundred day simple moving average of $15.82.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its earnings results on Monday, March 3rd. The company reported ($1.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.79). The company had revenue of $7.68 million for the quarter, compared to the consensus estimate of $86.32 million. As a group, equities analysts predict that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current fiscal year.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).